Breaking News on Global Pharmaceutical Technology & Manufacturing

Drug Delivery: Top Headlines

Novartis scoops GSK’s oncology portfolio, trades away its vaccine division

Novartis trades vaccines for oncology pipeline with GSK

23-Apr-2014 - Novartis has agreed to acquire GlaxoSmithKline’s oncology pipeline for as much as $16bn, while GSK will acquire Novartis’ vaccine business, excluding the flu vaccines, for as much as $7bn.

Related news

News in brief

Big Pharma pull out and share slump won’t silence RNAi advocates

22-Apr-2014 - RNA interference (RNAi) developers that saw stock prices fall after Novartis pulled out of the market last week have reiterated their belief in the therapeutic and revenue potential of gene silencing drugs. 

Hovione gets US patent for simple, patient-inspired inhaler

15-Apr-2014 - Hovione has obtained a US patent for a cheap capsule-based dry powder inhaler that it claims is cheaper for manufacturers to produce and easier for patients to use.

Pfizer, Novartis developing MenB vaccines to combat new strain

09-Apr-2014 - Recent outbreaks of a strain of meningitis, known as “serogroup B” or “MenB”, on US college campuses have caused both Pfizer and Novartis to develop new vaccines. 

Molecular Profiles' investment makes HME (bio)available for clients

08-Apr-2014 - Molecular Profiles has invested in hot melt extrusion (HME) and nano milling capabilities citing client demand for improving the bioavailablity of drugs.

Fiocruz to help make pediatric formulation of bitter schistosomiasis drug

08-Apr-2014 - A consortium developing treatments for children infected by parasitic worms has signed up Brazilian drugmaker Fiocruz to support upcoming clinical trials.

Two giant leaps for MannKind? US approval nod good for delivery tech too

02-Apr-2014 - A US FDA review panel has recommended that Afrezza be approved and concluded that the technology used to deliver MannKind's inhalable insulin does not damage airways or lung cells.

'Biodegradable battery' could be used to deliver drugs, researcher says

01-Apr-2014 - An intracochlear drug delivery implant could be powered over several months by a biodegradable battery according to an expert.

Drug Delivery: Featured news

Spotlight

EMA to rejig variations procedures and industry contact staff in April

EMA to rejig variations procedures and industry contact staff in April

Pharmaceutical firms working in Europe may need to update their address books next month after more reorganisation...

Janssen Button? Will GSK's F1 team up prompt other collaborations?

Janssen Button? Will GSK's F1 team up prompt other collaborations?

GSK has ‘smashed’ production targets at a UK inhaler plant by revving up manufacturing operations with knowhow...

Indian API maker slammed with US FDA Warning over data issues

Indian API maker slammed with US FDA Warning over data issues

Failure in maintaining test and production data has landed an Indian API maker with a Warning Letter...

US FDA issues new bioavailability guidelines

US FDA issues new bioavailability guidelines

The US FDA has published guidance of how sponsors should best document the bioavailability of products for...

Bioavailability breakthrough key to new cancer drug OKed in Japan

Bioavailability breakthrough key to new cancer drug OKed in Japan

Japan has become the first country to approve a new cancer pill that treats disease by interfering...

Key Industry Events

 

Access all events listing

Our events, Events from partners...